Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Lancet [Lancet] NLMUID: 2985213R"" wg kryterium: JN


Tytuł :
Breast cancer radiation therapy.
Autorzy :
Douek M; Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: .
De Silva-Minor S; Oxford University Hospitals Foundation Trust, Oxford, UK.
Davies L; Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 7DQ, UK.
Jones B; Department of Clinical Radiobiology, University of Oxford, Oxford OX3 7DQ, UK.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1558-1559.
Typ publikacji :
Letter; Comment
MeSH Terms :
Breast Neoplasms*/radiotherapy
Breast ; Disease Progression ; Humans ; Radiation Dose Hypofractionation
Opinia redakcyjna
Tytuł :
Breast cancer radiation therapy - Authors' reply.
Autorzy :
Brunt AM; School of Medicine, University of Keele, Staffordshire ST5 5BG, UK. Electronic address: .
Haviland JS; Institute of Cancer Research, Sutton, London, UK.
Wheatley DA; Royal Cornwall Hospital, Treliske, Truro, UK.
Yarnold JR; Institute of Cancer Research, Sutton, London, UK.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1559-1560.
Typ publikacji :
Letter; Comment
MeSH Terms :
Breast Neoplasms*/radiotherapy
Breast ; Humans ; Research
Opinia redakcyjna
Tytuł :
Breast cancer radiation therapy.
Autorzy :
Offersen BV; Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus 8200, Denmark; Department of Oncology, Aarhus University Hospital, Aarhus 8200, Denmark. Electronic address: .
Overgaard J; Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus 8200, Denmark.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1558.
Typ publikacji :
Letter; Comment
MeSH Terms :
Breast Neoplasms*/radiotherapy
Breast ; Disease Progression ; Humans ; Radiation Dose Hypofractionation
Opinia redakcyjna
Tytuł :
Breast cancer radiation therapy.
Autorzy :
McClelland S 3rd; Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Nov 14; Vol. 396 (10262), pp. 1559.
Typ publikacji :
Letter; Comment
MeSH Terms :
Breast Neoplasms*/radiotherapy
Breast ; Disease Progression ; Humans ; Radiation Dose Hypofractionation
Opinia redakcyjna
Tytuł :
Advancing immunotherapy for early-stage triple-negative breast cancer.
Autorzy :
Di Cosimo S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20100, Italy. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Oct 10; Vol. 396 (10257), pp. 1046-1048. Date of Electronic Publication: 2020 Sep 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Breast Neoplasms*
Neoadjuvant Therapy*
Albumins ; Anthracyclines ; Antibodies, Monoclonal, Humanized ; Double-Blind Method ; Humans ; Immunotherapy ; Paclitaxel
Czasopismo naukowe
Tytuł :
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Autorzy :
Murray Brunt A; University Hospitals of North Midlands and University of Keele, Stoke on Trent, UK; Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, London, UK. Electronic address: .
Haviland JS; Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, London, UK.
Wheatley DA; Royal Cornwall Hospital, Treliske, Truro, UK.
Sydenham MA; Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, London, UK.
Alhasso A; Beatson West of Scotland Cancer Centre, Glasgow, UK.
Bloomfield DJ; Brighton and Sussex University Hospitals, Brighton, UK.
Chan C; Nuffield Health Cheltenham Hospital, Cheltenham, UK.
Churn M; Worcestershire Acute Hospitals NHS Trust, Worcester, UK.
Cleator S; Imperial Healthcare NHS Trust, London, UK.
Coles CE; University of Cambridge, Cambridge, UK.
Goodman A; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; Torbay Hospital NHS Foundation Trust, Torquay, UK.
Harnett A; Norfolk and Norwich University Hospital, Norwich, UK.
Hopwood P; Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, London, UK.
Kirby AM; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
Kirwan CC; University of Manchester, Manchester, UK.
Morris C; Independent Cancer Patients' Voice, London, UK.
Nabi Z; Mount Vernon Cancer Centre, Northwood, UK.
Sawyer E; King's College London, London, UK.
Somaiah N; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
Stones L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, London, UK.
Syndikus I; Clatterbridge Cancer Centre, Bebington, Wirral, UK.
Bliss JM; Clinical Trials and Statistics Unit, The Institute of Cancer Research, Sutton, London, UK.
Yarnold JR; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
Pokaż więcej
Corporate Authors :
FAST-Forward Trial Management Group
Źródło :
Lancet (London, England) [Lancet] 2020 May 23; Vol. 395 (10237), pp. 1613-1626. Date of Electronic Publication: 2020 Apr 28.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms/*radiotherapy
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Mastectomy/methods ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Staging ; Radiation Dose Hypofractionation ; Radiation Injuries/epidemiology ; Radiation Injuries/etiology ; Radiotherapy, Adjuvant/adverse effects ; Radiotherapy, Adjuvant/methods ; Risk Assessment/methods ; Treatment Outcome ; United Kingdom/epidemiology
Czasopismo naukowe
Tytuł :
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Autorzy :
Spring LM; Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Wander SA; Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Andre F; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Moy B; Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Turner NC; Department of Medical Oncology, Royal Marsden Hospital, Institute of Cancer Research, London, UK.
Bardia A; Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Mar 07; Vol. 395 (10226), pp. 817-827.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Breast Neoplasms/*drug therapy
Cyclin-Dependent Kinase 4/*antagonists & inhibitors
Cyclin-Dependent Kinase 6/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
Cell Cycle/drug effects ; Clinical Trials as Topic ; Female ; Forecasting ; Humans ; Receptors, Estrogen ; Receptors, Progesterone
Czasopismo naukowe
Tytuł :
Protective strategies to prevent trastuzumab-induced cardiotoxicity.
Autorzy :
Guo S; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Tse G; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Liu T; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Feb 15; Vol. 395 (10223), pp. 491-492.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antineoplastic Agents*
Breast Neoplasms*
Cardiotoxicity ; Disease-Free Survival ; Humans ; Receptor, ErbB-2 ; Trastuzumab
Opinia redakcyjna
Tytuł :
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
Autorzy :
Earl HM; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Breast Cancer Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge, UK; National Institute for Health Research (NIHR), Cambridge Biomedical Research Centre, Cambridge, UK. Electronic address: .
Hiller L; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Plummer C; Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Freeman Hospital, Newcastle upon Tyne, UK.
Miles D; Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
Wardley AM; Research and Development, NIHR Manchester Clinical Research Facility, Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Cameron DA; Cancer Edinburgh Research Centre, The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Feb 15; Vol. 395 (10223), pp. 492-493.
Typ publikacji :
Letter; Comment
MeSH Terms :
Breast Neoplasms*
Cardiotoxicity*
Humans ; Receptor, ErbB-2 ; Trastuzumab
Opinia redakcyjna
Tytuł :
Carryover effects of aromatase inhibitors in prevention.
Autorzy :
Chumsri S; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: .
Thompson EA; Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2020 Jan 11; Vol. 395 (10218), pp. 91-92. Date of Electronic Publication: 2019 Dec 13.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Aromatase Inhibitors*
Breast Neoplasms*
Anastrozole ; Humans ; Receptors, Estrogen ; Tamoxifen
Czasopismo naukowe
Tytuł :
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Autorzy :
Cuzick J; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, UK. Electronic address: .
Sestak I; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, UK.
Forbes JF; Australia New Zealand Breast Cancer Trials Group Newcastle, University of Newcastle, Calvary Mater Hospital, Waratah, NSW, Australia.
Dowsett M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden, London, UK.
Cawthorn S; Breast Care Centre, Southmead Hospital, Bristol, UK.
Mansel RE; University Department of Surgery, University of Wales College of Medicine, Cardiff, UK.
Loibl S; German Breast Group, Frankfurt, Germany.
Bonanni B; Division of Chemoprevention and Genetics, European Institute of Oncology, Milan, Italy.
Evans DG; Prevent Breast Cancer Unit, Nightingale Breast Screening Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Howell A; Prevent Breast Cancer Unit, Nightingale Breast Screening Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Pokaż więcej
Corporate Authors :
IBIS-II investigators
Źródło :
Lancet (London, England) [Lancet] 2020 Jan 11; Vol. 395 (10218), pp. 117-122. Date of Electronic Publication: 2019 Dec 12.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anastrozole/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*prevention & control
Administration, Oral ; Adult ; Aged ; Anastrozole/adverse effects ; Breast Neoplasms/epidemiology ; Breast Neoplasms/mortality ; Carcinoma, Ductal, Breast/drug therapy ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Intraductal, Noninfiltrating/drug therapy ; Carcinoma, Intraductal, Noninfiltrating/pathology ; Female ; Follow-Up Studies ; Humans ; Incidence ; Middle Aged ; Placebos ; Treatment Outcome ; United Kingdom/epidemiology
Czasopismo naukowe
Tytuł :
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
Autorzy :
Whelan TJ; Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada. Electronic address: .
Julian JA; Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Berrang TS; Radiation Therapy Program, BC Cancer - Victoria, University of British Columbia, Vancouver, BC, Canada.
Kim DH; Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Germain I; Department of Radiation Oncology, CHU de Québec - Université Laval, Québec, QC, Canada.
Nichol AM; Division of Radiation Oncology, University of British Columbia and BC Cancer - Vancouver, BC, Canada.
Akra M; Department of Radiation Oncology, University of Manitoba, Winnipeg, MB, Canada.
Lavertu S; Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Germain F; Department of Radiation Oncology, CHU de Québec - Université Laval, Québec, QC, Canada; Division of Radiation Oncology, University of British Columbia and BC Cancer - Kelowna, BC, Canada.
Fyles A; Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Trotter T; University of Calgary, Calgary, AB, Canada.
Perera FE; Department of Oncology, Western University and London Regional Cancer Program, London, ON, Canada.
Balkwill S; BC Cancer - Surrey, BC, Canada.
Chafe S; Department of Oncology, Division of Radiation Oncology, University of Alberta and Cross Cancer Institute, Edmonton, AB, Canada.
McGowan T; Trillium Health Partners Credit Valley Hospital, Mississauga, ON, Canada.
Muanza T; Department of Oncology, McGill University and Jewish General Hospital Segal Cancer Centre, Montreal, QC, Canada.
Beckham WA; Department of Physics and Astronomy, University of Victoria and BC Cancer - Victoria, BC, Canada.
Chua BH; University of New South Wales and Prince of Wales Hospital, Sydney, NSW, Australia.
Gu CS; Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Levine MN; Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Olivotto IA; University of Calgary, Calgary, AB, Canada.
Pokaż więcej
Corporate Authors :
RAPID Trial Investigators
Źródło :
Lancet (London, England) [Lancet] 2019 Dec 14; Vol. 394 (10215), pp. 2165-2172. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Brachytherapy/*methods
Breast Neoplasms/*radiotherapy
Carcinoma in Situ/*radiotherapy
Carcinoma, Ductal, Breast/*radiotherapy
Aged ; Australia ; Breast Neoplasms/surgery ; Canada ; Carcinoma in Situ/pathology ; Carcinoma in Situ/surgery ; Carcinoma, Ductal, Breast/surgery ; Female ; Humans ; Mastectomy, Segmental ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local/prevention & control ; New Zealand ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł :
Accelerated partial breast irradiation: more questions than answers?
Autorzy :
Coles CE; Department of Oncology, University of Cambridge, Cambridge CB2 0QQ, UK. Electronic address: .
Bliss JM; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
Poortmans PM; Department of Radiation Oncology, Institut Curie, Paris, France; Université Paris Sciences et Lettres, Paris, France.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2019 Dec 14; Vol. 394 (10215), pp. 2127-2129. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Carcinoma, Intraductal, Noninfiltrating*
Breast Neoplasms/*surgery
Female ; Humans ; Mastectomy, Segmental ; Patient Selection ; Radiotherapy, Adjuvant
Czasopismo naukowe
Tytuł :
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Autorzy :
Vicini FA; NRG Oncology, Pittsburgh, PA, USA; MHP Radiation Oncology Institute, St Joseph Mercy Hospital Campus, Pontiac, MI, USA. Electronic address: .
Cecchini RS; NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.
White JR; NRG Oncology, Pittsburgh, PA, USA; Ohio State University Comprehensive Cancer Center-Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, OH, USA.
Arthur DW; NRG Oncology, Pittsburgh, PA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Julian TB; NRG Oncology, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
Rabinovitch RA; NRG Oncology, Pittsburgh, PA, USA; University of Colorado Cancer Center, Aurora, CO, USA.
Kuske RR; NRG Oncology, Pittsburgh, PA, USA; Arizona Breast Cancer Specialists, Arizona Center for Cancer Care, Scottsdale, AZ, USA.
Ganz PA; NRG Oncology, Pittsburgh, PA, USA; University of California at Los Angeles, Los Angeles, CA, USA.
Parda DS; NRG Oncology, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
Scheier MF; Carnegie Mellon University, Pittsburgh, PA, USA.
Winter KA; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA.
Paik S; NRG Oncology, Pittsburgh, PA, USA; Yonsei University College of Medicine, Seoul, Korea.
Kuerer HM; NRG Oncology, Pittsburgh, PA, USA; MD Anderson Cancer Center, Houston, TX, USA.
Vallow LA; Mayo Clinic Florida, Jacksonville, FL, USA.
Pierce LJ; Southwest Oncology Group Cancer Research Network, Hope Foundation for Cancer Research, Portland, OR, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Mamounas EP; NRG Oncology, Pittsburgh, PA, USA; Orlando Health, UF Health Cancer Center, Orlando, FL, USA.
McCormick B; NRG Oncology, Pittsburgh, PA, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Costantino JP; NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.
Bear HD; NRG Oncology, Pittsburgh, PA, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Germain I; NRG Oncology, Pittsburgh, PA, USA; Centre Hospitalier Universitaire de Québec-Université Laval, Pavillon Hôtel-Dieu de Québec, Québec City, QC, Canada.
Gustafson G; NRG Oncology, Pittsburgh, PA, USA; Community Clinical Oncology Program, William Beaumont Hospital, Sterling Heights, MI, USA.
Grossheim L; NRG Oncology, Pittsburgh, PA, USA; Summit Cancer Center, Post Falls, ID, USA.
Petersen IA; NRG Oncology, Pittsburgh, PA, USA; Mayo Clinic, Rochester, MN, USA.
Hudes RS; NRG Oncology, Pittsburgh, PA, USA; Saint Agnes Hospital, Baltimore, MD, USA; Thomas Jefferson University, Baltimore, MD, USA.
Curran WJ Jr; NRG Oncology, Pittsburgh, PA, USA; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Bryant JL; NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA.
Wolmark N; NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2019 Dec 14; Vol. 394 (10215), pp. 2155-2164. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :
Brachytherapy/*methods
Breast Neoplasms/*radiotherapy
Adult ; Aged ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Combined Modality Therapy ; Female ; Humans ; Lymphatic Metastasis ; Mammography ; Mastectomy, Segmental ; Middle Aged ; Neoplasm Grading ; Neoplasm Invasiveness ; Neoplasm Staging ; Prognosis ; Radiotherapy Dosage ; Survival Rate
Czasopismo naukowe
Tytuł :
Anaesthetic interventions and long-term tumour recurrence.
Autorzy :
Abdallah FW; Department of Anesthesiology and Pain Medicine, and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada; Department of Anesthesia, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada. Electronic address: .
Wijeysundera DN; Department of Anesthesia, University of Toronto, Toronto, ON, Canada; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada; Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada; Department of Anesthesia, St Michael's Hospital, Toronto, ON, Canada.
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2019 Nov 16; Vol. 394 (10211), pp. 1781-1782. Date of Electronic Publication: 2019 Oct 20.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Anesthetics*
Breast Neoplasms*
Anesthesia, General ; Humans ; Neoplasm Recurrence, Local
Czasopismo naukowe
Tytuł :
Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
Autorzy :
Sessler DI; Department of Outcomes Research, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: .
Pei L; Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, China.
Huang Y; Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, China. Electronic address: .
Fleischmann E; Department of Anaesthesia, General Intensive Care and Pain Management, Medical University of Vienna, Vienna, Austria.
Marhofer P; Department of Anaesthesia, General Intensive Care and Pain Management, Medical University of Vienna, Vienna, Austria.
Kurz A; Department of Outcomes Research, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Mayers DB; Department of Outcomes Research, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Regional Anesthesiology, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Meyer-Treschan TA; Department of Anesthesiology, University of Düsseldorf, Düsseldorf, Germany.
Grady M; Department of Outcomes Research, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Regional Anesthesiology, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Tan EY; Tan Tock Seng Hospital, Singapore, Singapore.
Ayad S; Department of Outcomes Research, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Regional Anesthesiology, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Mascha EJ; Department of Outcomes Research, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Quantitative Health Sciences, Anesthesiology Institute and Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Buggy DJ; Mater University Hospital, School of Medicine, University College Dublin, Dublin, Ireland.
Pokaż więcej
Corporate Authors :
Breast Cancer Recurrence Collaboration
Źródło :
Lancet (London, England) [Lancet] 2019 Nov 16; Vol. 394 (10211), pp. 1807-1815. Date of Electronic Publication: 2019 Oct 20.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Anesthesia, Conduction/*methods
Anesthesia, General/*methods
Breast Neoplasms/*surgery
Neoplasm Recurrence, Local/*prevention & control
Adult ; Aged ; Aged, 80 and over ; Analgesics, Opioid/adverse effects ; Analgesics, Opioid/therapeutic use ; Anesthesia, Conduction/adverse effects ; Anesthesia, General/adverse effects ; Anesthetics, Inhalation/adverse effects ; Breast Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Mastectomy/methods ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local/etiology ; Neoplasm Staging ; Nerve Block/methods ; Pain, Postoperative/prevention & control ; Sevoflurane/adverse effects
Czasopismo naukowe
Tytuł :
Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Corporate Authors :
Collaborative Group on Hormonal Factors in Breast Cancer
Źródło :
Lancet (London, England) [Lancet] 2019 Sep 28; Vol. 394 (10204), pp. 1159-1168. Date of Electronic Publication: 2019 Aug 29.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms/*epidemiology
Estrogens/*therapeutic use
Progesterone/*therapeutic use
Progestins/*therapeutic use
Adult ; Aged ; Drug Therapy, Combination ; Estrogen Replacement Therapy ; Female ; Humans ; Logistic Models ; Middle Aged ; Obesity/epidemiology ; Principal Component Analysis ; Risk ; Risk Factors ; Time Factors
Czasopismo naukowe
Tytuł :
Menopausal hormones: definitive evidence for breast cancer.
Autorzy :
Kotsopoulos J; Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5S1B2, Canada. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2019 Sep 28; Vol. 394 (10204), pp. 1116-1118. Date of Electronic Publication: 2019 Aug 29.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Breast Neoplasms*
Breast ; Hormone Replacement Therapy ; Humans ; Menopause
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies